Narcolepsy, Narcolepsy With Cataplexy, Narcolepsy Without Cataplexy
Conditions
Keywords
Narcolepsy, psychosocial, mindfulness, health-related quality of life, hypersomnia
Brief summary
The overall goal of this research is to test the effectiveness of a mindfulness-based intervention (MBI) for improving health-related quality of life as a complementary practice to standard care for narcolepsy. This study is a feasibility trial in which 60 adults with narcolepsy will be randomized to receive either a 4-week (brief), 8-week (standard), or 12-week (extended) MBI. Each MBI will be delivered in small groups using a live videoconferencing platform and teaches mindfulness practices to help cope with narcolepsy symptoms. By developing a scalable mind-body intervention, this project can addresses a major research gap on improving psychosocial functioning in people with narcolepsy.
Detailed description
Narcolepsy is a serious and debilitating condition involving persistent and excessive sleepiness that affects 1 in 2000 Americans and 3 million people worldwide. Although wake-promoting pharmacotherapy can reduce sleepiness there is no cure and people with narcolepsy experience significantly poor health-related quality of life, particularly in the domains of mental and social health. Therefore, the overarching goal of this research is to test the effectiveness of a mindfulness-based intervention (MBI) for improving health-related quality of life as a complementary practice to standard care for narcolepsy. The purpose of this study is to conduct a feasibility trial to determine the optimal parameters for adapting and delivering MBI to people with narcolepsy. The specific aims are to: 1) Determine the feasibility and acceptability of MBI delivered using videoconferencing for the purpose of improving psychosocial functioning in people with narcolepsy and 2) Determine the feasibility of recruitment and assessment methods for delivering MBI using videoconferencing. The feasibility trial includes 60 adults with narcolepsy who will be randomized to receive either a 4-week (brief), 8-week (standard), or 12-week (extended) MBI. Each MBI will be similar in content, which includes mindfulness practices and group discussions with adaptations for working with narcolepsy symptoms. All MBIs will be delivered in small groups using a live videoconferencing platform to enhance accessibility. If the findings of this project support the feasibility of further testing, the next project would be aimed at enhancing rigor and reproducibility (e.g., designing appropriate control, refining outcome measures and eligibility criteria) in preparation for a large-scale pragmatic trial. The overall significance of this research is to develop a scalable mind-body intervention that addresses a major research gap on improving psychosocial functioning in people with narcolepsy.
Interventions
The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat. The rationale for testing the short MBI is to evaluate a low-dose (8 hours of contact) MBI that optimizes cost-effectiveness and minimizes patient burden.
The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat. The length of this package is based on the standard length of MBSR as an 8-week program. The rationale for testing the standard MBI is to provide a comparison to a dose (16 hours of contact) that is most similar to the length of MBSR and has the fewest modifications, making it easier to train MBI providers.
The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks. Each group session will be two hours. The group sessions will be identical to the standard package except for the timing (every other week) of the last four sessions. In addition to the group sessions, the MBI provider will offer office hours in between the bi-weekly group sessions, where participants will be able to schedule individual sessions with the MBI provider to discuss questions and troubleshoot their mindfulness practice. In addition, participants will receive an all-day meditation retreat, similar to the other conditions. The rationale for testing the extended MBI is to optimize acceptability and uptake based on the investigator's preliminary data by allowing for a slower, extended pace of learning mindfulness practices with an opportunity to have individual discussions with the instructor (16 hours of contact + individual office hours).
Sponsors
Study design
Intervention model description
Participants are assigned to receive one of there different MBI treatments: 1) Brief MBI, 4 weeks, 2) Standard MBI, 8 weeks, 3) Extended MBI, 12 weeks
Eligibility
Inclusion criteria
1. Males and females age 18 and older (except when the age of majority for a state differs from 18, including Delaware \[19 years or older\], Mississippi \[21 years or older\], and Nebraska \[19 years or older\]) 2. ICSD-3 criteria (8) for Narcolepsy (Type I or II) 3. Endorse current psychological distress based on a t-score ≥ 60 on the PROMIS depression or anxiety scales 4. Established standard care for narcolepsy. Patients who have not been previously diagnosed will be required to complete a clinical work-up through a sleep clinic (i.e., nocturnal PSG followed by a next-day MSLT) before participating. Standard care is managed outside of the study.
Exclusion criteria
1. Hypersomnia not of central origin (i.e., hypersomnia attributed to psychiatric disorder, medical disorder, other sleep disorder such as circadian rhythm sleep disorder, or insufficient sleep). 2. Current suicidal ideation or intent. 3. Uncontrolled medical conditions or physical limitations that require immediate medical treatment that would prevent ability to engage in the treatment protocol. 4. Inability to engage in the treatment protocol due to a psychiatric (e.g., psychotic disorder) or cognitive issue. 5. Untreated moderate-to-severe sleep-related breathing disorder, defined as an apnea hypopnea index (AHI) ≥ 15. Those receiving treatment for a sleep-related breathing disorder and can demonstrate adequate management (e.g., residual AHI \< 5) will be allowed to participate. 6. Previous participation in a formal MBI program, such as MBSR. 7. Unstable dose of medications at the time of screening (e.g., stimulants). 8. Unable to attend intervention sessions due to accessibility (i.e., reliable internet connection) or availability (i.e., not available due to scheduling conflicts). 9. Currently living outside of the United States.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Attended ≥ 80% of Sessions | 4 weeks (Brief MBI), 8 weeks (Standard MBI), or 12 weeks (Extended MBI) | Number of participants who attended greater than or equal to 80% of sessions |
| Number of Participants Who Practiced Meditation ≥ 4 Days Per Week | 4 weeks (Brief MBI), 8 weeks (Standard MBI), or 12 weeks (Extended MBI) | Number of participants who practiced meditation greater than or equal to 4 days per week |
| Number of Participants Who Completed Assessments | Baseline and 4 weeks (Brief MBI), 8 weeks (Standard MBI), or 12 weeks (Extended MBI) | Number of participants who completed entire baseline and post-treatment assessment (questionnaires, actigraphy, and neurocognitive testing) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Negative Scale | Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks) | Measures the direct negative psychosocial effect related to illness with higher scores reflecting worse outcomes. Population mean (T-score) of 50 with a standard deviation of 10. |
| Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale | Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks) | Measures overall physical and mental health with higher scores reflecting better outcomes. Population mean (T-score) of 50 with a standard deviation of 10. |
| Self-Compassion Scale (SCS) | Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks) | The SCS assesses the acquisition of self-compassion. It is a 26-item self report measure with three main components of self-compassion: self-kindness vs. self-judgement, common humanity vs. isolation, and mindfulness vs. over-identification. The total score ranges from 1-5, with higher scores reflecting more self-compassion. |
| Patient Reported Outcomes Measurement Information System (PROMIS) Depression Scale | Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks) | Measures depressive symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting more depressive symptoms (worse outcome). Population mean (T-score) of 50 with a standard deviation of 10. |
| Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale | Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks) | Measures anxiety symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting more anxiety symptoms (worse outcome). Population mean (T-score) of 50 with a standard deviation of 10. |
| Five Facet Mindfulness Questionnaire (FFMQ) | Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks) | The FFMQ assesses the acquisition of mindfulness skills. It is a 39-item self-report measure that consists of five factors representing elements of mindfulness: observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience. Total scores range from 39-195, with higher scores reflecting more mindfulness. |
| Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Positive | Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks) | Measures the direct positive psychosocial effect related to illness with higher scores reflecting better outcomes. Population mean (T-score) of 50 with a standard deviation of 10. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Brief MBI The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat.
Brief MBI: The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat. The rationale for testing the short MBI is to evaluate a low-dose (8 hours of contact) MBI that optimizes cost-effectiveness and minimizes patient burden. | 20 |
| Standard MBI The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat.
Standard MBI: The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat. The length of this package is based on the standard length of MBSR as an 8-week program. The rationale for testing the standard MBI is to provide a comparison to a dose (16 hours of contact) that is most similar to the length of MBSR and has the fewest modifications, making it easier to train MBI providers. | 20 |
| Extended MBI The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks, with optional office hoursin between the bi-weekly group sessions and one all day meditation retreat.
Extended MBI: The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks. Each group session will be two hours. The group sessions will be identical to the standard package except for the timing (every other week) of the last four sessions. In addition to the group sessions, the MBI provider will offer office hours in between the bi-weekly group sessions, where participants will be able to schedule individual sessions with the MBI provider to discuss questions and troubleshoot their mindfulness practice. In addition, participants will receive an all-day meditation retreat, similar to the other conditions. The rationale for testing the extended MBI is to optimize acceptability and uptake based on the investigator's preliminary data by allowing for a slower, extended pace of learning mindfulness practices with an opportunity to have individual discussions with the instructor (16 hours of contact + individual office hours). | 20 |
| Total | 60 |
Baseline characteristics
| Characteristic | Brief MBI | Standard MBI | Extended MBI | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 1 Participants | 2 Participants | 3 Participants |
| Age, Categorical Between 18 and 65 years | 20 Participants | 19 Participants | 18 Participants | 57 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 2 Participants | 2 Participants | 6 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 18 Participants | 18 Participants | 18 Participants | 54 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Patient-Reported Outcomes Measurement Information System Depression | 59.53 T-Score STANDARD_DEVIATION 4.76 | 56.11 T-Score STANDARD_DEVIATION 4.81 | 60.06 T-Score STANDARD_DEVIATION 6.25 | 58.57 T-Score STANDARD_DEVIATION 5.52 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 0 Participants | 2 Participants | 3 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 18 Participants | 20 Participants | 17 Participants | 55 Participants |
| Sex/Gender, Customized Female | 16 Participants | 17 Participants | 20 Participants | 53 Participants |
| Sex/Gender, Customized Male | 3 Participants | 2 Participants | 0 Participants | 5 Participants |
| Sex/Gender, Customized Non-binary | 1 Participants | 1 Participants | 0 Participants | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 20 | 0 / 20 | 0 / 20 |
| other Total, other adverse events | 7 / 20 | 5 / 20 | 1 / 20 |
| serious Total, serious adverse events | 0 / 20 | 1 / 20 | 0 / 20 |
Outcome results
Number of Participants Who Attended ≥ 80% of Sessions
Number of participants who attended greater than or equal to 80% of sessions
Time frame: 4 weeks (Brief MBI), 8 weeks (Standard MBI), or 12 weeks (Extended MBI)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Brief MBI | Number of Participants Who Attended ≥ 80% of Sessions | 15 Participants |
| Standard MBI | Number of Participants Who Attended ≥ 80% of Sessions | 13 Participants |
| Extended MBI | Number of Participants Who Attended ≥ 80% of Sessions | 15 Participants |
Number of Participants Who Completed Assessments
Number of participants who completed entire baseline and post-treatment assessment (questionnaires, actigraphy, and neurocognitive testing)
Time frame: Baseline and 4 weeks (Brief MBI), 8 weeks (Standard MBI), or 12 weeks (Extended MBI)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Brief MBI | Number of Participants Who Completed Assessments | 18 Participants |
| Standard MBI | Number of Participants Who Completed Assessments | 13 Participants |
| Extended MBI | Number of Participants Who Completed Assessments | 16 Participants |
Number of Participants Who Practiced Meditation ≥ 4 Days Per Week
Number of participants who practiced meditation greater than or equal to 4 days per week
Time frame: 4 weeks (Brief MBI), 8 weeks (Standard MBI), or 12 weeks (Extended MBI)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Brief MBI | Number of Participants Who Practiced Meditation ≥ 4 Days Per Week | 16 Participants |
| Standard MBI | Number of Participants Who Practiced Meditation ≥ 4 Days Per Week | 8 Participants |
| Extended MBI | Number of Participants Who Practiced Meditation ≥ 4 Days Per Week | 13 Participants |
Five Facet Mindfulness Questionnaire (FFMQ)
The FFMQ assesses the acquisition of mindfulness skills. It is a 39-item self-report measure that consists of five factors representing elements of mindfulness: observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience. Total scores range from 39-195, with higher scores reflecting more mindfulness.
Time frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
Population: Post-treatment scores not available for participants who did not complete the assessment
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Brief MBI | Five Facet Mindfulness Questionnaire (FFMQ) | Baseline | 115.90 score on a scale | Standard Deviation 24.8 |
| Brief MBI | Five Facet Mindfulness Questionnaire (FFMQ) | Post-treatment | 132.42 score on a scale | Standard Deviation 21.91 |
| Standard MBI | Five Facet Mindfulness Questionnaire (FFMQ) | Baseline | 122.50 score on a scale | Standard Deviation 22.13 |
| Standard MBI | Five Facet Mindfulness Questionnaire (FFMQ) | Post-treatment | 144.00 score on a scale | Standard Deviation 16.11 |
| Extended MBI | Five Facet Mindfulness Questionnaire (FFMQ) | Baseline | 107.00 score on a scale | Standard Deviation 13.43 |
| Extended MBI | Five Facet Mindfulness Questionnaire (FFMQ) | Post-treatment | 136.53 score on a scale | Standard Deviation 19.42 |
Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale
Measures anxiety symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting more anxiety symptoms (worse outcome). Population mean (T-score) of 50 with a standard deviation of 10.
Time frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
Population: Post-treatment scores not available for participants who did not complete the assessment
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Brief MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale | Baseline | 62.54 T-score | Standard Deviation 7.04 |
| Brief MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale | Post-treatment | 62.46 T-score | Standard Deviation 9.79 |
| Standard MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale | Baseline | 61.24 T-score | Standard Deviation 4.85 |
| Standard MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale | Post-treatment | 56.62 T-score | Standard Deviation 6.25 |
| Extended MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale | Baseline | 61.69 T-score | Standard Deviation 6.67 |
| Extended MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale | Post-treatment | 58.04 T-score | Standard Deviation 7.48 |
Patient Reported Outcomes Measurement Information System (PROMIS) Depression Scale
Measures depressive symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting more depressive symptoms (worse outcome). Population mean (T-score) of 50 with a standard deviation of 10.
Time frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
Population: Post-treatment scores not available for participants who did not complete the assessment
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Brief MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Depression Scale | Baseline | 59.53 T-score | Standard Deviation 4.76 |
| Brief MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Depression Scale | Post-treatment | 57.70 T-score | Standard Deviation 9.08 |
| Standard MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Depression Scale | Baseline | 56.11 T-score | Standard Deviation 4.81 |
| Standard MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Depression Scale | Post-treatment | 53.89 T-score | Standard Deviation 6.3 |
| Extended MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Depression Scale | Baseline | 60.06 T-score | Standard Deviation 6.25 |
| Extended MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Depression Scale | Post-treatment | 52.73 T-score | Standard Deviation 6.08 |
Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale
Measures overall physical and mental health with higher scores reflecting better outcomes. Population mean (T-score) of 50 with a standard deviation of 10.
Time frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
Population: Post-treatment scores not available for participants who did not complete the assessment
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Brief MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale | Global Mental Health (Baseline) | 38.01 T-score | Standard Deviation 7.89 |
| Brief MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale | Global Mental Health (Post-treatment) | 41.17 T-score | Standard Deviation 10.09 |
| Brief MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale | Global Physical Health (Baseline) | 46.32 T-score | Standard Deviation 7.46 |
| Brief MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale | Global Physical Health (Post-treatment) | 47.41 T-score | Standard Deviation 8.16 |
| Standard MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale | Global Physical Health (Post-treatment) | 46.32 T-score | Standard Deviation 6.82 |
| Standard MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale | Global Mental Health (Baseline) | 40.43 T-score | Standard Deviation 6.07 |
| Standard MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale | Global Physical Health (Baseline) | 43.85 T-score | Standard Deviation 6.15 |
| Standard MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale | Global Mental Health (Post-treatment) | 44.77 T-score | Standard Deviation 7.35 |
| Extended MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale | Global Physical Health (Post-treatment) | 45.12 T-score | Standard Deviation 8.32 |
| Extended MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale | Global Mental Health (Post-treatment) | 42.73 T-score | Standard Deviation 8.09 |
| Extended MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale | Global Physical Health (Baseline) | 43.71 T-score | Standard Deviation 6.44 |
| Extended MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale | Global Mental Health (Baseline) | 36.03 T-score | Standard Deviation 7.82 |
Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Negative Scale
Measures the direct negative psychosocial effect related to illness with higher scores reflecting worse outcomes. Population mean (T-score) of 50 with a standard deviation of 10.
Time frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
Population: Post-treatment scores not available for participants who did not complete the assessment
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Brief MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Negative Scale | Baseline | 60.94 T-score | Standard Deviation 6.53 |
| Brief MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Negative Scale | Post-treatment | 58.70 T-score | Standard Deviation 10.09 |
| Standard MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Negative Scale | Baseline | 59.35 T-score | Standard Deviation 5.28 |
| Standard MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Negative Scale | Post-treatment | 56.52 T-score | Standard Deviation 6.24 |
| Extended MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Negative Scale | Baseline | 62.59 T-score | Standard Deviation 8.26 |
| Extended MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Negative Scale | Post-treatment | 57.28 T-score | Standard Deviation 6.75 |
Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Positive
Measures the direct positive psychosocial effect related to illness with higher scores reflecting better outcomes. Population mean (T-score) of 50 with a standard deviation of 10.
Time frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
Population: Post-treatment scores not available for participants who did not complete the assessment
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Brief MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Positive | Baseline | 39.35 T-score | Standard Deviation 8 |
| Brief MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Positive | Post-treatment | 42.83 T-score | Standard Deviation 8.92 |
| Standard MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Positive | Baseline | 42.07 T-score | Standard Deviation 6.84 |
| Standard MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Positive | Post-treatment | 46.94 T-score | Standard Deviation 8.26 |
| Extended MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Positive | Baseline | 38.74 T-score | Standard Deviation 7.23 |
| Extended MBI | Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Positive | Post-treatment | 43.85 T-score | Standard Deviation 9.02 |
Self-Compassion Scale (SCS)
The SCS assesses the acquisition of self-compassion. It is a 26-item self report measure with three main components of self-compassion: self-kindness vs. self-judgement, common humanity vs. isolation, and mindfulness vs. over-identification. The total score ranges from 1-5, with higher scores reflecting more self-compassion.
Time frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
Population: Post-treatment scores not available for participants who did not complete the assessment
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Brief MBI | Self-Compassion Scale (SCS) | Baseline | 2.66 score on a scale | Standard Deviation 0.8 |
| Brief MBI | Self-Compassion Scale (SCS) | Post-treatment | 3.12 score on a scale | Standard Deviation 0.86 |
| Standard MBI | Self-Compassion Scale (SCS) | Baseline | 2.91 score on a scale | Standard Deviation 0.82 |
| Standard MBI | Self-Compassion Scale (SCS) | Post-treatment | 3.58 score on a scale | Standard Deviation 0.58 |
| Extended MBI | Self-Compassion Scale (SCS) | Baseline | 2.52 score on a scale | Standard Deviation 0.5 |
| Extended MBI | Self-Compassion Scale (SCS) | Post-treatment | 3.61 score on a scale | Standard Deviation 0.61 |